The chemotherapy response score is a useful histological predictor of prognosis in high‐grade serous carcinoma
- 11 December 2017
- journal article
- research article
- Published by Wiley in Histopathology
- Vol. 72 (4) , 619-625
Abstract
Aims: High‐grade serous carcinoma (HGSC) is the most common tubal/ovarian malignant tumour, and usually presents at an advanced stage. Interval debulking surgery (IDS) after neoadjuvant chemotherapy (NACT) is being increasingly used for the management of these patients. The chemotherapy response score (CRS) has been proposed for grading the response of tubo‐ovarian HGSC to NACT on the basis of examination of IDS specimens. Our aims were to evaluate the CRS in post‐NACT cases, assess the interobserver agreement, and correlate it with overall and progression‐free survival.Methods and results: The CRS was applied by two independent pathologists on omental and adnexal tumour tissue sections from post‐NACT patients with HGSC who had undergone IDS. The assigned primary site of tumour origin was documented. The interobserver agreement and prognostic significance of the CRS were evaluated. There were 103 cases, and in 61.1% of cases a fallopian tubal origin was confirmed. There were 26, 35 and 42 cases with CRSs of 1, 2, and 3, respectively. The interobserver variability for CRS was low (κ = 0.806). The CRS showed a significant correlation with progression‐free survival (CRS 1 and 2 versus 3: median survival 16 months versus 18 months; P = 0.004); however, after controlling for debulking status, this association was not significant. The CRS applied to adnexal sections did not show any prognostic significance for either progression‐free or overall survival.Conclusion: The CRS is an easy and reproducible method for predicting the prognosis in post‐NACT HGSC patients.Keywords
This publication has 21 references indexed in Scilit:
- Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous CarcinomaJournal of Clinical Oncology, 2015
- Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)Laboratory Investigation, 2015
- Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trialThe Lancet, 2015
- Assignment of primary site in high‐grade serous tubal, ovarian and peritoneal carcinoma: a proposalHistopathology, 2014
- Origin and molecular pathogenesis of ovarian high-grade serous carcinomaAnnals of Oncology, 2013
- Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian CancerInternational Journal of Gynecological Cancer, 2011
- Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin?American Journal of Surgical Pathology, 2010
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerNew England Journal of Medicine, 2010
- Carcinoma of the OvaryInternational Journal of Gynecology & Obstetrics, 2006
- Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trialAmerican Journal of Obstetrics and Gynecology, 2005